Synthyra LogoSynthyra

The Platform

The interactome,
answerable in seconds.

Synthyra builds protein language models that screen any protein or molecule against the entire proteome: 375 million interactions per second, across species. Proteome-scale interaction mapping and protein design for medical research and biosecurity.

The Problem

We grasp the parts. The connections are what's missing.

The human proteome contains over 20,000 proteins and more than 400 million possible pairwise interactions. Existing databases catalog only a fraction of them. The rest are untested, unpublished, unknown. Synthyra screens the relevant interaction space for each query and returns a ranked hypothesis map: predicted partners, functional annotations, pathway enrichment, and a structure model for follow-up.

0%

of drugs fail clinical trials

0%

because of unmanageable toxicity

$0M+

average cost of late-stage failure

The Engine

Atlas

A chemical language model that predicts protein-protein and protein-ligand interactions at proteome scale. The engine behind every query.

Proteome-Scale

Screen against all 20,000+ human proteins in a single query

Real-Time

375 million interactions per second

Validated

AUROC 0.82 with wet-lab confirmed designs

Atlas in context

Atlas makes biology navigable.

The same model can connect ligands to confident targets, trace nearby protein neighborhoods, and project those signals back into biological features researchers already use.

Explore all demos

PLI + PPI

How Atlas connects ligands to pathways.

FDA ligands highlight confident protein targets, then show the PPI neighborhoods likely to be perturbed.

Loading PLI + PPI

SwissBioPics

Cell maps by SIB Swiss Institute of Bioinformatics, CC BY 4.0

Value

Three pillars. One platform.

Faster Cures

Query any target protein and generate ranked interaction hypotheses, confidence scores, pathway enrichment, and functional annotations for follow-up experiments.

Life Sciences Hypothesis Workflow

Rapid Defense

Screen pathogen proteins against the full human proteome in seconds to protect national security and respond to emerging threats. Predict cross-species interactions across 8+ organisms, including novel host-pathogen pairs no database has cataloged.

Biosecurity Suite

Safer Drugs

Screen drug candidates against the entire proteome to surface off-target interactions. Functional annotations flag solubility, stability, and localization risks before you reach the clinic.

Safety & Toxicity Suite

Solutions

Purpose-built product suites.

Focused maps for teams that need to turn latent biological structure into ranked hypotheses, risk decisions, and actionable response.

Safety & Toxicity

PLI context for off-target risk.

Atlas PLI places FDA-approved ligands and human protein targets on the same map, turning off-target screening into a navigable risk surface before clinic-bound programs harden.

34.1M high-confidence PLI edges across FDA ligand and protein space.

  • FDA-approved drug neighborhoods

  • Proteome-wide off-target hypotheses

  • Protein target context for mechanism and safety narratives

Explore Atlas PLI
Dark Atlas PLI TMAP showing PLINDER and FDA-approved ligand context

Biosecurity

Inter-actomes for host-pathogen response.

Atlas maps pathogen and human proteomes in one interaction field so teams can triage host-pathogen edges, exposed host systems, and countermeasure routes, turning an emerging threat into a navigable target list in hours, not months.

Cross-species actome views spanning pathogen and human proteins.

  • Host-pathogen edge prioritization for rapid response

  • Human target context for countermeasure design

  • Cross-organism interaction maps built for national-security timelines

Open inter-actome
Atlas inter-actome map between E. coli K-12 and human proteins

Validation

Built on evidence. Verified in the lab.

Independent benchmarks, third-party wet-lab validation, millions of open-source downloads, billions of protein interactions screened.

+13%

MCC vs current state-of-the-art

Matthews Correlation Coefficient, Bernett Gold-standard PPI benchmark

0.70-0.78 AUROC

Intra-species interactions, consistent across taxonomic diversity

Human, mouse, yeast, D. melanogaster, E. coli, C. elegans, D. rerio, A. thaliana.

0.60-0.90 AUROC

Inter-species interactions, first better than random chance on human|sars-cov-2 interactions

human|sars-cov-2, human|sars-cov, human|hpv, human|hiv, human|hhv, human|mouse, human|rat, human|yeast, BIOGRID

0

AUROC: Core PPI prediction

Internal held-out evaluation sets, homology-aware clustering (30%), C3 dataset split by cluster

0

Novel predicted interactions characterized, 80 more on the way

BLI validation, Adaptyv Bio (third-party)

2.6M+

Model downloads

First version was open-source, global researcher adoption

Binding visualization

EGFR Binder Case Study

Wet-Lab Confirmed

Synthyra designed a variant of cetuximab (in orange), a multi-billion dollar cancer therapeutic, with 87% stronger binding affinity (630 pM Kd) to EGFR (in green). 13 designs tested, 11 strong binders, 1 medium binder, 5 sub 3 nM Kd, 6 stronger than cetuximab.

Biolayer Interferometry on recombinant targets, SDS-PAGE QC. Adaptyv Bio

STRING vs. Atlas

From known interactions to ranked hypotheses.

STRING is the gold standard for known protein interactions. Atlas turns the unknown space around proteins and small molecules into hypotheses teams can test.

STRING

  • Excellent for exploring established biology
  • Catalogs interactions from literature, experiments, databases, and computational evidence
  • Coverage follows available evidence and periodic database updates
  • Does not generate proteome-scale PPI and PLI hypotheses from a single query

Atlas

  • Generates ranked PPI and PLI hypotheses at proteome scale
  • Surfaces interaction networks for untested proteins and small molecules
  • Adds functional annotations, pathway enrichment, and structure models for follow-up
  • Supports life-sciences workflows across safety, toxicity, and biodefense

STRING tells you what's known. Atlas helps generate what to test next.

The Destination

Beyond discovery, engineering biology itself.

The same platform that protects national security and accelerates medical research today is the foundation for our longer-term destination: metabolic engineering. We're designing biological systems to replace petrochemical processes, a powerful, green alternative to traditional synthetic chemistry.

Climate change

Engineer biological routes to fuels, materials, and chemicals that displace carbon-intensive petrochemistry.

Resource depletion

Build renewable, biology-driven manufacturing that breaks dependence on finite fossil feedstocks.

Human health

Turn proteome-scale understanding into the design of systems that confront disease at its source.

The interactome, answerable in seconds.

Request access to Discover and turn a protein or small molecule into a ranked life-sciences hypothesis map before the next experiment is designed.

or reach out at [email protected]

Synthyra

The interactome, answerable in seconds.

DemosBlogInitiativesSign In
Terms of ServicePrivacy Policy

© 2026 Synthyra. The interactome, answerable in seconds. All rights reserved.